Profile data is unavailable for this security.
About the company
Demant A/S, formerly William Demant Holding A/S, is a Denmark-based company engaged in the healthcare industry. It develops, manufactures and sells products and equipment designed to aid the hearing and communication of individuals. The Group focuses on four business areas: Hearing Devices, including such brands as Bernafon, Oticon, Frontrow, Phonic Ear and Sonic; Hearing Implants, including Oticon Medical; Diagnostic Instruments, comprising operations of such audiometer companies as Interacoustics, Grason-Stadler, Amplivox, Maico and MedRx, and Personal Communication, which includes the business of Sennheiser Communications, a headset producer. The Company operates globally, through more than 90 subsidiaries and associates worldwide.
- Revenue in DKK (TTM)22.97bn
- Net income in DKK2.37bn
- Incorporated1983
- Employees26.70k
- LocationDemant A/SKongebakken 9SMOERUM 2765DenmarkDNK
- Phone+45 39177300
- Fax+45 39277900
- Websitehttps://www.demant.com/
Mergers & acquisitions
| Acquired company | DEMANT:CPH since announced | Transaction value |
|---|---|---|
| Kind GmbH & Co KG | -35.40% | 799.61m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitrolife AB | 2.43bn | -3.54bn | 8.58bn | 1.15k | -- | 1.54 | -- | 3.53 | -37.01 | -37.01 | 25.39 | 58.29 | 0.2407 | 3.44 | 5.24 | 2,987,837.00 | -35.09 | -9.46 | -36.79 | -9.86 | 58.24 | 57.81 | -145.74 | -49.19 | 2.73 | 11.33 | 0.169 | -- | -4.68 | 22.53 | -1,077.00 | -- | 68.15 | 6.58 |
| AddLife AB | 7.38bn | 395.78m | 12.25bn | 2.30k | 31.99 | 3.29 | 12.64 | 1.66 | 4.60 | 4.60 | 85.69 | 44.66 | 0.8105 | 3.83 | 5.87 | 4,549,891.00 | 4.36 | 3.82 | 6.05 | 5.80 | 38.09 | 37.80 | 5.38 | 4.66 | 0.6257 | 3.68 | 0.4671 | 31.71 | 1.52 | 14.64 | 122.22 | 1.58 | 22.47 | 0.00 |
| Embla Medical hf | 5.83bn | 523.41m | 13.45bn | 4.19k | 25.50 | 2.39 | 14.85 | 2.31 | 1.23 | 1.23 | 13.64 | 13.08 | 0.5681 | 2.27 | 6.96 | 1,391,418.00 | 5.12 | 4.60 | 6.10 | 5.43 | 62.30 | 62.25 | 9.01 | 7.99 | 0.9445 | 7.22 | 0.3768 | 0.00 | 8.63 | 8.09 | 22.05 | 68.07 | 6.12 | -- |
| Elekta AB (publ) | 12.42bn | 206.37m | 14.47bn | 4.48k | 72.65 | 2.51 | 12.98 | 1.17 | 0.7646 | 0.7646 | 45.97 | 22.11 | 0.5781 | 3.35 | 3.09 | 3,872,796.00 | 0.9511 | 3.48 | 1.70 | 6.21 | 38.17 | 38.22 | 1.65 | 6.02 | 0.7918 | 7.51 | 0.4724 | 92.20 | -0.5685 | 4.29 | -81.80 | -26.22 | 15.56 | 5.92 |
| Asker Healthcare Group AB | 11.60bn | 331.47m | 19.13bn | 4.51k | 36.88 | -- | 22.04 | 1.65 | 1.92 | 1.92 | 54.47 | -- | 1.15 | 5.10 | 9.34 | 5,010,379.00 | 3.37 | -- | 4.36 | -- | 40.43 | -- | 2.94 | -- | 0.9924 | 3.40 | 0.4561 | -- | 11.69 | -- | 77.34 | -- | -- | -- |
| Ambu A/S | 6.09bn | 544.00m | 20.31bn | 5.43k | 42.29 | 3.82 | 22.01 | 3.34 | 2.04 | 2.04 | 22.85 | 22.64 | 0.8135 | 1.95 | 7.18 | 1,130,201.00 | 7.27 | 4.06 | 8.49 | 4.82 | 60.07 | 59.33 | 8.94 | 5.48 | 1.67 | 20.74 | 0.0845 | 21.23 | 11.98 | 11.10 | 159.15 | 20.37 | -2.24 | 7.17 |
| Sectra AB | 1.58bn | 456.84m | 25.59bn | 1.32k | 59.24 | 21.41 | 47.58 | 16.18 | 3.36 | 3.36 | 11.62 | 9.29 | 0.6688 | -- | 3.93 | 1,726,353.00 | 19.32 | 15.75 | 35.74 | 29.92 | 54.43 | 60.29 | 28.89 | 22.41 | -- | -- | 0.0505 | 19.27 | 19.85 | 4.47 | 31.51 | 18.87 | 7.19 | -- |
| Getinge AB | 24.72bn | 1.60bn | 37.07bn | 11.79k | 24.90 | 1.91 | 12.03 | 1.50 | 8.29 | 8.29 | 128.39 | 108.05 | 0.5808 | 2.91 | 5.36 | -- | 3.78 | 4.48 | 4.94 | 5.91 | 47.63 | 47.54 | 6.51 | 7.57 | 0.8595 | 7.05 | 0.2696 | 47.51 | 0.6042 | 3.24 | 37.85 | -6.96 | 4.69 | 9.63 |
| Demant A/S | 22.97bn | 2.37bn | 39.57bn | 26.70k | 16.52 | 3.97 | -- | 1.72 | 11.21 | 7.31 | 108.71 | 46.67 | 0.6423 | 2.19 | 5.94 | 860,208.20 | 6.62 | 8.82 | 8.18 | 12.44 | 75.62 | 75.44 | 10.30 | 12.49 | 1.00 | 5.69 | 0.6791 | 0.00 | 2.46 | 9.69 | -18.09 | 16.13 | 5.16 | -- |
| Coloplast A/S | 27.89bn | 3.99bn | 103.40bn | 16.98k | 27.78 | 8.03 | 18.94 | 3.71 | 17.71 | 17.71 | 123.79 | 61.25 | 0.5743 | 2.38 | 6.12 | 1,625,729.00 | 8.21 | 12.75 | 10.44 | 17.10 | 67.87 | 67.86 | 14.30 | 18.95 | 0.8122 | 9.75 | 0.6451 | 100.37 | 3.12 | 8.49 | -28.03 | -2.83 | 8.92 | 5.02 |
| Holder | Shares | % Held |
|---|---|---|
| Canada Pension Plan Investment Boardas of 31 Mar 2024 | 4.44m | 2.07% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 3.05m | 1.43% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 1.82m | 0.85% |
| FIL Investments Internationalas of 31 Dec 2025 | 1.78m | 0.83% |
| BI Asset Management Fondsm�glerselskab A/Sas of 30 Jan 2026 | 1.75m | 0.82% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 1.55m | 0.73% |
| Nykredit Bank A/S (Investment Management)as of 31 Jan 2026 | 1.34m | 0.63% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 1.29m | 0.61% |
| Geode Capital Management LLCas of 05 Feb 2026 | 1.08m | 0.50% |
| Danske Bank A/S (Investment Management)as of 31 Jan 2026 | 1.01m | 0.47% |
